December 12, 2016 / 1:29 PM / 7 months ago

BRIEF-Merck & Co updates on triple-negative breast cancer study

1 Min Read

Dec 12 (Reuters) - Merck & Co Inc

* Merck & Co inc says study is being conducted under an existing clinical trial collaboration agreement between two companies

* Interim results from phase 1b/2 study evaluating the combination of merck's keytruda (pembrolizumab) and eisai's halaven (eribulin mesylate) injection in metastatic triple-negative breast cancer presented at 2016 san antonio breast cancer symposium Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below